Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1993 Nov;92(5):2440–2447. doi: 10.1172/JCI116851

Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action.

Y J Lidor 1, K C O'Briant 1, F J Xu 1, T C Hamilton 1, R F Ozols 1, R C Bast Jr 1
PMCID: PMC288428  PMID: 8227359

Abstract

Alkylating agents can be administered in high dosage to patients with ovarian cancer using autologous bone marrow support, but drug-resistant tumor cells can still persist. Immunotoxins provide reagents that might eliminate drug resistant cells. In the present study, concurrent treatment with alkylators and immunotoxins proved superior to treatment with each agent alone. Toxin immunoconjugates prepared from different monoclonal antibodies and recombinant ricin A chain (rRTA) inhibited clonogenic growth of ovarian cancer cell lines in limiting dilution assays. When alkylating agents and toxin conjugates were used in combination, the addition of the immunotoxins to cisplatin, or to cisplatin and thiotepa, produced synergistic cytotoxic activity against the OVCA 432 and OVCAR III cell lines. Studies performed to clarify the mechanism of action showed that cisplatin and thiotepa had no influence on internalization and binding of the 317G5-rRTA immunotoxin. Intracellular uptake of [195m]Pt-cisplatin was not affected by the immunoconjugate and thiotepa. The combination of the 317G5-rRTA and thiotepa, as well as 317G5-rRTA alone, increased [195m]Pt cisplatin-DNA adduct levels. The immunotoxin alone and in combination with the alkylators decreased intracellular glutathione levels and reduced glutathione-S-transferase activity. Repair of DNA damage induced by the combination of alkylators and 317G5-rRTA was significantly reduced when compared to repair after damage with alkylators alone. These findings suggest that immunotoxins affect levels and activity of enzymes required for the prevention and repair of alkylator damage.

Full text

PDF
2440

Images in this article

2442Image
on p.2442
2442Image
on p.2442
2442Image
on p.2442
2442Image
on p.2442
2443Image
on p.2443
2443Image
on p.2443
2445Image
on p.2445
2445Image
on p.2445

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arrick B. A., Nathan C. F. Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res. 1984 Oct;44(10):4224–4232. [PubMed] [Google Scholar]
  2. Bast R. C., Jr, De Fabritiis P., Lipton J., Gelber R., Maver C., Nadler L., Sallan S., Ritz J. Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Res. 1985 Feb;45(2):499–503. [PubMed] [Google Scholar]
  3. Bast R. C., Jr, Feeney M., Lazarus H., Nadler L. M., Colvin R. B., Knapp R. C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981 Nov;68(5):1331–1337. doi: 10.1172/JCI110380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Berenbaum M. C. Synergy, additivism and antagonism in immunosuppression. A critical review. Clin Exp Immunol. 1977 Apr;28(1):1–18. [PMC free article] [PubMed] [Google Scholar]
  5. Berenbaum M. C. What is synergy? Pharmacol Rev. 1989 Jun;41(2):93–141. [PubMed] [Google Scholar]
  6. Bjorn M. J., Ring D., Frankel A. Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins. Cancer Res. 1985 Mar;45(3):1214–1221. [PubMed] [Google Scholar]
  7. Blythman H. E., Casellas P., Gros O., Gros P., Jansen F. K., Paolucci F., Pau B., Vidal H. Immunotoxins: hybrid molecules of monoclonal antibodies and a toxin subunit specifically kill tumour cells. Nature. 1981 Mar 12;290(5802):145–146. doi: 10.1038/290145a0. [DOI] [PubMed] [Google Scholar]
  8. Bohr V. A. Gene specific damage and repair after treatment of cells with UV and chemotherapeutical agents. Adv Exp Med Biol. 1991;283:225–233. doi: 10.1007/978-1-4684-5877-0_22. [DOI] [PubMed] [Google Scholar]
  9. Boyer C. M., Borowitz M. J., McCarty K. S., Jr, Kinney R. B., Everitt L., Dawson D. V., Ring D., Bast R. C., Jr Heterogeneity of antigen expression in benign and malignant breast and ovarian epithelial cells. Int J Cancer. 1989 Jan 15;43(1):55–60. doi: 10.1002/ijc.2910430113. [DOI] [PubMed] [Google Scholar]
  10. Caporossi D., Bacchetti S., Nicoletti B. Synergism between aphidicolin and adenoviruses in the induction of breaks at fragile sites on human chromosomes. Cancer Genet Cytogenet. 1991 Jul 1;54(1):39–53. doi: 10.1016/0165-4608(91)90028-s. [DOI] [PubMed] [Google Scholar]
  11. Creasman W. T., DiSaia P. J. Screening in ovarian cancer. Am J Obstet Gynecol. 1991 Jul;165(1):7–10. doi: 10.1016/0002-9378(91)90213-b. [DOI] [PubMed] [Google Scholar]
  12. DiSaia P. J. Concerns about ovarian epithelial cancer management. Am J Clin Oncol. 1987 Jun;10(3):268–269. doi: 10.1097/00000421-198706000-00022. [DOI] [PubMed] [Google Scholar]
  13. Dijt F. J., Fichtinger-Schepman A. M., Berends F., Reedijk J. Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. Cancer Res. 1988 Nov 1;48(21):6058–6062. [PubMed] [Google Scholar]
  14. Du D. L., Volpe D. A., Grieshaber C. K., Murphy M. J., Jr Effects of L-phenylalanine mustard and L-buthionine sulfoximine on murine and human hematopoietic progenitor cells in vitro. Cancer Res. 1990 Jul 1;50(13):4038–4043. [PubMed] [Google Scholar]
  15. Eastman A., Schulte N. Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry. 1988 Jun 28;27(13):4730–4734. doi: 10.1021/bi00413a022. [DOI] [PubMed] [Google Scholar]
  16. Endo Y., Mitsui K., Motizuki M., Tsurugi K. The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by the toxins. J Biol Chem. 1987 Apr 25;262(12):5908–5912. [PubMed] [Google Scholar]
  17. Fidler I. J., Poste G. The cellular heterogeneity of malignant neoplasms: implications for adjuvant chemotherapy. Semin Oncol. 1985 Sep;12(3):207–221. [PubMed] [Google Scholar]
  18. Friedman H. S., Skapek S. X., Colvin O. M., Elion G. B., Blum M. R., Savina P. M., Hilton J., Schold S. C., Jr, Kurtzberg J., Bigner D. D. Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma. Cancer Res. 1988 Oct 1;48(19):5397–5402. [PubMed] [Google Scholar]
  19. Fry D. W., Jackson R. C. Membrane transport alterations as a mechanism of resistance to anticancer agents. Cancer Surv. 1986;5(1):47–79. [PubMed] [Google Scholar]
  20. Fuster C., Miró R., Barrios L., Egozcue J. Telomere association of chromosomes induced by aphidicolin in a normal individual. Hum Genet. 1990 Apr;84(5):424–426. doi: 10.1007/BF00195813. [DOI] [PubMed] [Google Scholar]
  21. Gershenson D. M., Kavanagh J. J., Copeland L. J., Stringer C. A., Morris M., Wharton J. T. Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy. Obstet Gynecol. 1989 May;73(5 Pt 1):798–802. [PubMed] [Google Scholar]
  22. Goldie J. H., Coldman A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1727–1733. [PubMed] [Google Scholar]
  23. Green J. A., Vistica D. T., Young R. C., Hamilton T. C., Rogan A. M., Ozols R. F. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res. 1984 Nov;44(11):5427–5431. [PubMed] [Google Scholar]
  24. Griffith O. W. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem. 1980 Jul 15;106(1):207–212. doi: 10.1016/0003-2697(80)90139-6. [DOI] [PubMed] [Google Scholar]
  25. Habig W. H., Pabst M. J., Jakoby W. B. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem. 1974 Nov 25;249(22):7130–7139. [PubMed] [Google Scholar]
  26. Hamilos D. L., Zelarney P., Mascali J. J. Lymphocyte proliferation in glutathione-depleted lymphocytes: direct relationship between glutathione availability and the proliferative response. Immunopharmacology. 1989 Nov-Dec;18(3):223–235. doi: 10.1016/0162-3109(89)90020-9. [DOI] [PubMed] [Google Scholar]
  27. Hamilton T. C., Young R. C., McKoy W. M., Grotzinger K. R., Green J. A., Chu E. W., Whang-Peng J., Rogan A. M., Green W. R., Ozols R. F. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 1983 Nov;43(11):5379–5389. [PubMed] [Google Scholar]
  28. Jakoby W. B. Glutathione transferases: an overview. Methods Enzymol. 1985;113:495–499. doi: 10.1016/s0076-6879(85)13064-8. [DOI] [PubMed] [Google Scholar]
  29. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  30. Lai G. M., Ozols R. F., Young R. C., Hamilton T. C. Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. J Natl Cancer Inst. 1989 Apr 5;81(7):535–539. doi: 10.1093/jnci/81.7.535. [DOI] [PubMed] [Google Scholar]
  31. Lidor Y. J., Shpall E. J., Peters W. P., Bast R. C., Jr Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer. Int J Cancer. 1991 Nov 11;49(5):704–710. doi: 10.1002/ijc.2910490513. [DOI] [PubMed] [Google Scholar]
  32. Louie K. G., Behrens B. C., Kinsella T. J., Hamilton T. C., Grotzinger K. R., McKoy W. M., Winker M. A., Ozols R. F. Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res. 1985 May;45(5):2110–2115. [PubMed] [Google Scholar]
  33. Lund B., Williamson P. Prognostic factors for outcome of and survival after second-look laparotomy in patients with advanced ovarian carcinoma. Obstet Gynecol. 1990 Oct;76(4):617–622. [PubMed] [Google Scholar]
  34. Masuda H., Ozols R. F., Lai G. M., Fojo A., Rothenberg M., Hamilton T. C. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res. 1988 Oct 15;48(20):5713–5716. [PubMed] [Google Scholar]
  35. Masuho Y., Zalutsky M., Knapp R. C., Bast R. C., Jr Interaction of monoclonal antibodies with cell surface antigens of human ovarian carcinomas. Cancer Res. 1984 Jul;44(7):2813–2819. [PubMed] [Google Scholar]
  36. Moazed D., Robertson J. M., Noller H. F. Interaction of elongation factors EF-G and EF-Tu with a conserved loop in 23S RNA. Nature. 1988 Jul 28;334(6180):362–364. doi: 10.1038/334362a0. [DOI] [PubMed] [Google Scholar]
  37. Neal J. L. Analysis of Michaelis kinetics for two independent, saturable membrane transport functions. J Theor Biol. 1972 Apr;35(1):113–118. doi: 10.1016/0022-5193(72)90196-8. [DOI] [PubMed] [Google Scholar]
  38. Ozols R. F., Cowan K. New aspects of clinical drug resistance: the role of gene amplification and the reversal of resistance in drug refractory cancer. Important Adv Oncol. 1986:129–157. [PubMed] [Google Scholar]
  39. Ozols R. F., O'Dwyer P. J., Hamilton T. C., Young R. C. The role of glutathione in drug resistance. Cancer Treat Rev. 1990 Dec;17 (Suppl A):45–50. doi: 10.1016/0305-7372(90)90015-8. [DOI] [PubMed] [Google Scholar]
  40. Ozols R. F., Young R. C. Ovarian cancer. Curr Probl Cancer. 1987 Mar-Apr;11(2):57–122. doi: 10.1016/s0147-0272(87)80004-1. [DOI] [PubMed] [Google Scholar]
  41. Pinto A. L., Lippard S. J. Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA. Biochim Biophys Acta. 1985;780(3):167–180. doi: 10.1016/0304-419x(85)90001-0. [DOI] [PubMed] [Google Scholar]
  42. Pirker R., FitzGerald D. J., Hamilton T. C., Ozols R. F., Laird W., Frankel A. E., Willingham M. C., Pastan I. Characterization of immunotoxins active against ovarian cancer cell lines. J Clin Invest. 1985 Sep;76(3):1261–1267. doi: 10.1172/JCI112082. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Ramakrishnan S., Bjorn M. J., Houston L. L. Recombinant ricin A chain conjugated to monoclonal antibodies: improved tumor cell inhibition in the presence of lysosomotropic compounds. Cancer Res. 1989 Feb 1;49(3):613–617. [PubMed] [Google Scholar]
  44. Reed E., Yuspa S. H., Zwelling L. A., Ozols R. F., Poirier M. C. Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. J Clin Invest. 1986 Feb;77(2):545–550. doi: 10.1172/JCI112335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Robichaud N. J., Fram R. J. Schedule dependence of buthionine sulfoximine in reversing resistance to cisplatin. Chem Biol Interact. 1990;76(3):333–342. doi: 10.1016/0009-2797(90)90100-2. [DOI] [PubMed] [Google Scholar]
  46. Scanlon K. J., Safirstein R. L., Thies H., Gross R. B., Waxman S., Guttenplan J. B. Inhibition of amino acid transport by cis-diamminedichloroplatinum(II) derivatives in L1210 murine leukemia cells. Cancer Res. 1983 Sep;43(9):4211–4215. [PubMed] [Google Scholar]
  47. Sessa C., Zucchetti M., Davoli E., Califano R., Cavalli F., Frustaci S., Gumbrell L., Sulkes A., Winograd B., D'Incalci M. Phase I and clinical pharmacological evaluation of aphidicolin glycinate. J Natl Cancer Inst. 1991 Aug 21;83(16):1160–1164. doi: 10.1093/jnci/83.16.1160. [DOI] [PubMed] [Google Scholar]
  48. Smyth M. J. Glutathione modulates activation-dependent proliferation of human peripheral blood lymphocyte populations without regulating their activated function. J Immunol. 1991 Mar 15;146(6):1921–1927. [PubMed] [Google Scholar]
  49. Steel G. G., Peckham M. J. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys. 1979 Jan;5(1):85–91. doi: 10.1016/0360-3016(79)90044-0. [DOI] [PubMed] [Google Scholar]
  50. Stewart D. J., Evans W. K. Non-chemotherapeutic agents that potentiate chemotherapy efficacy. Cancer Treat Rev. 1989 Mar;16(1):1–40. doi: 10.1016/0305-7372(89)90002-9. [DOI] [PubMed] [Google Scholar]
  51. Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem. 1969 Mar;27(3):502–522. doi: 10.1016/0003-2697(69)90064-5. [DOI] [PubMed] [Google Scholar]
  52. Trosko J. E., Yager J. D. A sensitive method to measure physical and chemical carcinogen-induced "unscheduled DNA synthesis" in rapidly dividing eukaryotic cells. Exp Cell Res. 1974 Sep;88(1):47–55. doi: 10.1016/0014-4827(74)90616-8. [DOI] [PubMed] [Google Scholar]
  53. Willingham M. C., FitzGerald D. J., Pastan I. Pseudomonas exotoxin coupled to a monoclonal antibody against ovarian cancer inhibits the growth of human ovarian cancer cells in a mouse model. Proc Natl Acad Sci U S A. 1987 Apr;84(8):2474–2478. doi: 10.1073/pnas.84.8.2474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Yu Y. H., Crews J. R., Cooper K., Ramakrishnan S., Houston L. L., Leslie D. S., George S. L., Lidor Y., Boyer C. M., Ring D. B. Use of immunotoxins in combination to inhibit clonogenic growth of human breast carcinoma cells. Cancer Res. 1990 Jun 1;50(11):3231–3238. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES